ライフサイエンスコーパス: cPLA2

1 he activation of group IVA phospholipase A2 (cPLA2).

2 tion of group IV cytosolic phospholipase A2 (cPLA2).

3 gs of the 85-kDa cytosolic phospholipase A2 (cPLA2).

4 n also activated cytosolic phospholipase A2 (cPLA2).

5 phospholipids by cytosolic phospholipase A2 (cPLA2).

6 sphatidylcholine vesicle binding affinity of cPLA2.

7 e cells with fluorescent protein chimeras of cPLA2.

8 on of other annexins as well as of COX-2 and cPLA2.

9 th the dexamethasone-mediated suppression of cPLA2.

10 h accompanied enhanced catalytic activity of cPLA2.

11 ynthesis, but not for the phosphorylation of cPLA2.

12 mediated by calcium-triggered activation of cPLA2.

13 e believe is a novel inherited deficiency of cPLA2.

14 terfering with the intracellular movement of cPLA2.

15 tes and this is necessary for stimulation of cPLA2.

16 When compared to the C2 domain from cPLA2, a similar orientation for the beta-sandwich regio

17 ation (herbimycin) inhibited the increase in cPLA2 activation and AA release.

18 98059) significantly inhibited sPLA2-induced cPLA2 activation and AA release.

19 Our data suggest that cPLA2 activation and its catalytic product platelet-acti

20 FB mediate hypoxia-induced Src-PLD1-PKCgamma-cPLA2 activation and retinal neovascularization via acti

21 t1 blocked hypoxia-induced Src-PLD1-PKCgamma-cPLA2 activation and retinal neovascularization.

22 attenuated hypoxia-induced Src-PLD1-PKCgamma-cPLA2 activation and retinal neovascularization.

23 of these results, we propose a mechanism for cPLA2 activation by calcium and phosphorylation.

24 We also studied the results of cPLA2 activation by epidermal growth factor (EGF) and ca

25 derstand the mechanisms of Src-PLD1-PKCgamma-cPLA2 activation by vascular endothelial growth factor A

26 rosine phosphorylation and Src-PLD1-PKCgamma-cPLA2 activation in HRMVECs.

27 sessments were used to test whether blocking cPLA2 activation pharmacologically or genetically reduce

28 ctively, the results suggest a model whereby cPLA2 activation regulates Group V sPLA2 expression, whi

29 Notably, the SCI-induced cPLA2 activation was mediated by the extracellular signa

30 so inhibited VEGFA-induced Src-PLD1-PKCgamma-cPLA2 activation, but only modestly.

31 a2+ availability is a dispensable signal for cPLA2 activation, which suggests the existence of altern

32 nflammatory cells, completely independent of cPLA2 activation.

33 cing signal transduction events that lead to cPLA2 activation.

34 s are involved in the regulation of group IV cPLA2 activation.

35 505 phosphorylation partially contributes to cPLA2 activation.

36 r attenuated VEGFA-induced Src-PLD1-PKCgamma-cPLA2 activation.

37 with FcepsilonRI-mediated events leading to cPLA2 activation.

38 Deactivating MYC lowered cPLA2 activity along with COX2 and 5-LOX mRNA levels.

39 partially purified sPLA2 from BMMC enhanced cPLA2 activity and AA release.

40 PLA2 to BMMC caused a transient increase in cPLA2 activity and translocation of this activity to mem

41 opyranoside BSA, also induced an increase in cPLA2 activity in BMMC.

42 of the 16:4(n-3)-GPR120 axis led to enhanced cPLA2 activity in these splenic macrophages and secretio

43 Embryonic cPLA2 activity remained constant from the 1-cell stage u

44 The inhibition of cPLA2 activity resulted in the blockade of the chlamydia

45 ion nor cPLA2 phosphorylation; consequently, cPLA2 activity was not affected by hVPLA2.

46 Inhibition of cPLA2 activity with AACOCF3 increased DNA synthesis in R

47 residence is important in the regulation of cPLA2 activity, we explored the contributions of the C2

48 del membranes and hence in the regulation of cPLA2 activity.

49 eneration, via the regulation of the Src and cPLA2 activity.

50 d an increase in cytosolic phospholipase A2 (cPLA2) activity with a preferential release of membrane-

51 ibited tumor cell growth, phosphorylation of cPLA2 alpha promoted growth and counteracted Smad-mediat

52 expression of cPLA2alpha, but inhibition of cPLA2 alpha, cyclooxygenase-2 (COX-2), or EP1 receptor r

53 ies the action of cytosolic phospholipase A2(cPLA2) alpha in regulating eicosanoid biosynthesis by mo

54 pase A2, and the cytosolic phospholipase A2 (cPLA2)alpha isoform has been specifically shown to direc

55 ntained transcripts and protein for group IV cPLA2-alpha and cPLA2-gamma.

56 ective for cleavage at sn-2 as compared with cPLA2-alpha and cPLA2-gamma.

57 rs at micromolar Ca2+ concentrations for the cPLA2-alpha C2 domain, but requires 3- and 10-fold highe

58 The greater Ca2+ sensitivity of the cPLA2-alpha domain results from its higher intrinsic Ca2

59 Docking of the cPLA2-alpha domain to zwitterionic lipids is triggered b

60 ctively, require greater than 400 ms for the cPLA2-alpha domain, compared to 13 ms for the PKC-beta d

61 Finally, the recombinant C2 domain of cPLA2-alpha exhibited calcium-independent membrane bindi

62 LA2-beta, that has significant homology with cPLA2-alpha in both the calcium-dependent lipid binding

63 e, thrombin or the calcium ionophore A23187, cPLA2-alpha relocated to intracellular membranes.

64 A-AM demonstrated that a substantial pool of cPLA2-alpha remained associated with membrane fractions

65 timulation with calcium-mobilizing agonists, cPLA2-alpha translocates to intracellular phospholipid m

66 Calcium-independent membrane association of cPLA2-alpha was not due to hydrophobic or cytoskeletal i

67 is study, the calcium-induced association of cPLA2-alpha with EA.hy.926 endothelial cell membranes wa

68 Cytosolic phospholipase A2-alpha (cPLA2-alpha) is a calcium-activated enzyme involved in a

69 proteins: cytosolic phospholipase A2-alpha (cPLA2-alpha), protein kinase C-beta (PKC-beta), and syna

70 s the generation of free arachidonic acid by cPLA2-alpha, this enzyme has become an attractive pharma

71 n of calcium-independent membrane-associated cPLA2-alpha.

72 et membrane play a role in the regulation of cPLA2-alpha.

73 estigate whether cytosolic phospholipase A2 (cPLA2 ), an important isoform of PLA2 that mediates the

74 inated regulation of two metabolic pathways (cPLA2 and 5-lipoxygenase), which results in the generati

75 e pathway by up-regulating expression of the cPLA2 and 5-LOX genes.

76 Up-regulation of cPLA2 and 5-LOX in middle ear epithelial cells was accom

77 genes that govern the lipoxygenase pathway, cPLA2 and 5-LOX, was observed in rats following inoculat

78 fferent human PLA2s: the cytosolic Group IVA cPLA2 and calcium-independent Group VIA iPLA2.

79 JAK3 activity reduced the phosphorylation of cPLA2 and COX-2 protein levels.

80 for 18 h, i.e., a lag in phosphorylation of cPLA2 and ERK1/2 lasting 30 s before its eventual rise.

81 The kinetics of cPLA2 and ERK1/2 phosphorylation following stimulation w

82 te a change in the intracellular position of cPLA2 and found that cPLA2 did not translocate normally

83 two human cytosolic PLA2 enzymes: group IVA cPLA2 and group VIA iPLA2.

84 ExoU interacts in vitro with an inhibitor of cPLA2 and iPLA2 enzymes and contains a putative serine-a

85 catalytic dyad homologous to those found in cPLA2 and iPLA2 enzymes.

86 cytosolic and the calcium-independent PLA2s (cPLA2 and iPLA2), are key enzymes mediating oligomeric a

87 ds and putative membrane-binding residues of cPLA2 and measured the effects of mutations on its enzym

88 When HEK293 cells transfected with cPLA2 and mutants were stimulated with ionomycin, the wi

89 this study we investigated the influence of cPLA2 and secreted phospholipase A2 (sPLA2) Group IIA, G

90 d5 is accompanied by the rapid activation of cPLA2 and the cPLA2-dependent release of [3H]arachidonic

91 Pharmacological inhibition of cPLA2 and the hVPLA2-induced activation of eosinophils d

92 on of both chlamydial activation of the host cPLA2 and uptake of glycerophospholipids from the host c

93 blocked by various inhibitors of cytosolic (cPLA2) and Ca2+ -independent (iPLA2) phospholipase A2 en

94 osphorylation of cytosolic phospholipase A2 (cPLA2) and consequent thromboxane A2 (TXA2) production.

95 gh expression of cytosolic phospholipase A2 (cPLA2) and cyclooxygenase (COX) 2.

96 the kinetics of cytosolic phospholipase A2 (cPLA2) and extracellular signal-regulated kinase (ERK1/2

97 the function of cytosolic phospholipase A2 (cPLA2) and its role in membrane regulation at the Golgi

98 osphorylation of cytosolic phospholipase A2 (cPLA2), and arachidonic acid (AA) and LTC4 release follo

99 holipase A2 (PLA2), Group IV cytosolic PLA2 (cPLA2), and cyclooxygenase-2 (COX-2).

100 itor of cPLA2, short interfering RNA against cPLA2, and several calcium signaling blockers, indicatin

101 ted in increased interaction between p11 and cPLA2, anti-cPLA2 antibodies were used to immunoprecipit

102 ased interaction between p11 and cPLA2, anti-cPLA2 antibodies were used to immunoprecipitate p11.cPLA

103 ere activated by an autocrine loop involving cPLA2, arachidonic acid release, COX-2-dependent PGI(2)

104 ines, IL-1beta and IL-6, thereby identifying cPLA2 as an important regulator of the inflammatory prog

105 It was over 70 times more selective for the cPLA2 as compared with the human nonpancreatic secreted

106 atic activity of cytosolic phospholipase A2 (cPLA2) as at-tested to by arachidonic acid release withi

107 thiol antioxidant NAC reduces activation of cPLA2 (assessed by isoform gel-shift and membrane transl

108 cPLA2 association with Golgi was slower than the isolate

109 report the X-ray crystal structure of human cPLA2 at 2.5 A. cPLA2 consists of an N-terminal calcium-

110 ms of cPLA2, we show that phosphorylation of cPLA2 at both Ser-505 and Ser-727 and elevation of Ca(2+

111 blocked collagen-induced phosphorylation of cPLA2 at its two phosphorylation sites in vivo, Ser505 a

112 shift of cPLA2 induced by phosphorylation of cPLA2 at various sites.

113 Since inhibition of iPLA2, but not cPLA2, attenuated IgM binding to apoptotic cells, these

114 al SAPK cascades and that phosphorylation of cPLA2 augments arachidonic acid release.

115 Transient expression of cPLA2-beta cDNA in COS cells results in an increase in c

116 cPLA2-beta is markedly less selective for cleavage at sn

117 Northern analysis reveals a cPLA2-beta transcript of 8 kilobase pairs that is expres

118 cDNA encoding a 1012-amino acid polypeptide cPLA2-beta, that has significant homology with cPLA2-alp

119 With the identification of cPLA2-beta, the newly defined cPLA2 family now comprises

120 eading to LTC4 generation by phosphorylating cPLA2, but not histamine release or IL-4 production, in

121 In vitro, activation of cPLA2 by ceramide-1-phosphate or A23187 induced spinal n

122 g surface on the Ca2+-activated C2 domain of cPLA2 by engineering a single cysteine substitution at 1

123 The current paradigm for activation of cPLA2 by stimuli proposes that both an increase in intra

124 swelling of cells and their nuclei activates cPla2 by translocating it from the nucleoplasm to the nu

125 The isolated cPLA2 C2 domain associated with Golgi membranes rapidly

126 beta-sandwich region is found; however, the cPLA2 C2 domain is translocated 5-7 A deeper into the me

127 ing the high-resolution crystal structure of cPLA2-C2 as a starting point, we embedded two copies of

128 the C2 domain of cytosolic phospholipase A2 (cPLA2-C2) in a 1-palmitoyl-2-oleoyl-phosphatidylcholine

129 These results demonstrate a role for the cPLA2 catalytic domain in regulating membrane associatio

130 Cytosolic phospholipase A2 (cPLA2) catalyzes release of arachidonic acid from membra

131 Activated cytosolic phospholipase (cPLA2) catalyzes the production of arachidonic acid, whi

132 ntibodies were used to immunoprecipitate p11.cPLA2 complexes and Western blots of the immunoprecipita

133 y crystal structure of human cPLA2 at 2.5 A. cPLA2 consists of an N-terminal calcium-dependent lipid-

134 s that host cell cytosolic phospholipase A2 (cPLA2) contributes to E. coli K1 invasion of BMECs but n

135 Cytosolic phospholipase A2 (cPLA2) controls AA generation.

136 The GIVD cPLA2 (cPLA2delta) is a potential drug target for develo

137 and activity of cytosolic phospholipase A2 (cPLA2), cyclooxygenase-2 (COX-2), and production of PGs.

138 eover small inhibitory RNAs directed against cPLA2 decreased the effect of A23187 and EGF on IL-8 and

139 d activation of eosinophils derived from the cPLA2-deficient mouse corroborated that hVPLA2 mediates

140 rachidonic acid release and translocation of cPLA2, demonstrating the requirement for a functional C2

141 lecithin induces susceptibility through both cPLA2-dependent and -independent pathways.

142 ied by the rapid activation of cPLA2 and the cPLA2-dependent release of [3H]arachidonic acid ([3H]AA)

143 tracellular position of cPLA2 and found that cPLA2 did not translocate normally in infected cells, ra

144 ined the role of cytosolic phospholipase A2 (cPLA2) during human eosinophil adherence to ICAM-1- or V

145 Blocking activity of cPLA2 efficiently suppressed expression of inflammatory

146 icating the presence of one or more group IV cPLA2 enzymes.

147 dentify protein residues in the C2 domain of cPLA2 essential for its Ca2+ and membrane binding, we se

148 ound to be the most potent inhibitor of GIVA cPLA2, exhibiting an XI(50) value of 0.011 mole fraction

149 SCI significantly increased cPLA2 expression and activation.

150 ntification of cPLA2-beta, the newly defined cPLA2 family now comprises three members that may have d

151 pts and protein for group IV cPLA2-alpha and cPLA2-gamma.

152 age at sn-2 as compared with cPLA2-alpha and cPLA2-gamma.

153 kedly altering basal and cytokine-stimulated cPLA2 gene expression in intestinal epithelial cells, le

154 uation were used to access expression of the cPLA2 gene in rat small intestinal epithelial and mouse

155 occurs through a direct reduction of de novo cPLA2 gene transcription.

156 These results demonstrate that cPLA2 has an influence on IL-8 and COX 2 gene and protei

157 ich the gene for cytosolic phospholipase A2 (cPLA2) has been disrupted to demonstrate the absolute re

158 Group IVA cytosolic phospholipase A2 (cPLA2) has been shown to play a critical role in the ago

159 ression of a previously identified zebrafish cPLA2 homologue.

160 ly IL-3 priming results from preconditioning cPLA2, i.e., causing its phosphorylation, while late pri

161 c Abeta(1-42) to increase phosphorylation of cPLA2 in astrocytes through the NADPH oxidase and mitoge

162 to demonstrate the absolute requirement for cPLA2 in both the immediate and the delayed phases of ei

163 0 minutes postinjury or genetically deleting cPLA2 in mice ameliorated motor deficits, and reduced ce

164 allow the sustained membrane interaction of cPLA2 in response to transient calcium increases.

165 However, no studies addressed the role of cPLA2 in the regulation of cholesterol-rich membranes th

166 fluorophosphonate suggest a key role for the cPLA2 in the response as well.

167 kinases MNK1, MSK1, and PRAK1 phosphorylate cPLA2 in vitro uniquely on Ser-727 as shown by mass spec

168 s were able to phosphorylate wild-type human cPLA2 in vitro, although to different extents, but not c

169 er expression of cytosolic phospholipase A2 (cPLA2) in H596 cells than that of A549 cells.

170 nd activation of cytosolic phospholipase A2 (cPLA2) in intact cells remain to be fully characterized.

171 donyl-selective, cytosolic phospholipase A2 (cPLA2) in intestinal cells.

172 iates the release of AA and leukotriene in a cPLA2-independent manner.

173 This cPLA2-independent pathway involved changes in cell membr

174 oth pathways, it was sufficient only for the cPLA2-independent pathway.

175 ts on the membrane binding and activation of cPLA2, indicating that two calcium ions bound to the C2

176 accompanied by a time-dependent gel shift of cPLA2 induced by phosphorylation of cPLA2 at various sit

177 However, cPLA2 inhibition neither prevented CBRM1/5 expression no

178 ion of arachidonic acid to eosinophils after cPLA2 inhibition with arachidonyl trifluoromethylketone

179 nship of 2-oxoamide-based compounds and GIVA cPLA2 inhibition.

180 eatment with the most potent 2-oxoester GIVA cPLA2 inhibitor resulted in over 50% decrease in KLA-eli

181 chidonyl trifluoromethyl ketone, a selective cPLA2 inhibitor, and was confirmed with BMEC derived fro

182 Methyl arachidonyl fluorophosphate, a cPLA2 inhibitor, inhibited the effect of A23187 and of E

183 sed by arachidonyl trifluoromethyl ketone, a cPLA2 inhibitor.

184 s suppressed by AACOCF3, a phospholipase A2 (cPLA2) inhibitor.

185 donic acid release are abrogated by group IV cPLA2 inhibitors (methyl arachidonyl fluorophosphate and

186 up leads to highly potent and selective GIVA cPLA2 inhibitors (X I(50) values 0.00007-0.00008) and do

187 roup IV cPLA2, to infected MPhi treated with cPLA2 inhibitors completely restored the antimycobacteri

188 ion of GV sPLA2, and none of the potent GIVA cPLA2 inhibitors inhibited either GV sPLA2 or GVIA iPLA2

189 the development of potent and selective GIVA cPLA2 inhibitors is of great importance.

190 The novel, highly potent and selective GIVA cPLA2 inhibitors provide excellent tools for the study o

191 Importantly, group IV cPLA2 inhibitors significantly reduced MPhi antimycobact

192 Two of these specific GIVA cPLA2 inhibitors were also found to have potent therapeu

193 The structurally unrelated cPLA2 inhibitors, arachidonyl trifluoromethylketone and

194 Our data suggest that cPLA2 is a substrate for several SAPK cascades and that

195 Whereas cPLA2 is essential for immediate eicosanoid generation b

196 ding loops show that the membrane binding of cPLA2 is largely driven by hydrophobic interactions resu

197 y, while the FMLP-induced phosphorylation of cPLA2 is not affected by the inhibitors of the p38 MAP k

198 cPLA2 is phosphorylated on multiple sites in Sf9 cells;

199 cPLA2 is regulated by phosphorylation and by calcium, wh

200 iPLA2 is the dominant PLA2 in rat brain, and cPLA2 is the most abundant PLA2 in P388D1 macrophages an

201 both NIH3T3 and MC3T3E1 cells suggests that cPLA2 is the most likely enzyme that catalyzes the relea

202 How tissue damage is sensed to activate cPLA2 is unknown.

203 Cytosolic phospholipase A2 (cPLA2) is a Ca2+-dependent enzyme that mediates agonist-

204 e Group IVA cytosolic phospholipase A2 (GIVA cPLA2) is a key provider of substrates for the productio

205 Cytosolic group IV phospholipase A2 (cPLA2) is a ubiquitously expressed enzyme with key roles

206 previously that cytosolic phospholipase A2 (cPLA2) is able to activate gene expression through PPAR-

207 The C2 domain of cytosolic phospholipase A2 (cPLA2) is involved in the Ca2+-dependent membrane bindin

208 man platelets, cytosolic phospholipase A(2) (cPLA2) is phosphorylated on Ser-505 by p38 protein kinas

209 riments show that cytosolic phospholipase 2 (cPLA2) is the key enzyme mediating the p25-induced LPC p

210 Cytosolic phospholipase A2 (GIVA cPLA2) is the only PLA2 that exhibits a marked preferenc

211 Group IVA cytosolic phospholipase A2 (GIVA cPLA2) is the rate-limiting provider of pro-inflammatory

212 that sPLA2 isoforms (pla2g5, 12a, and 12b), cPLA2 isoform (pla2g4a), iPLA2 isoform (pla2g6), and PLA

213 l migration in vitro Genetic ablation of the cPLA2 isoform cPLA2alpha dramatically reduced lung infla

214 gamma interferon, or their combination, and cPLA2-IVA mediated the release of arachidonic acid, whic

215 The expression of cPLA2-IVA was increased in response to M. tuberculosis,

216 marrow-derived macrophages (BMDMs) expressed cPLA2-IVA, cPLA2-IVB, iPLA2-VI, sPLA2-IIE, and sPLA2-XII

217 r survival of M. tuberculosis was similar in cPLA2-IVA-deficient and wild-type macrophages.

218 ved macrophages (BMDMs) expressed cPLA2-IVA, cPLA2-IVB, iPLA2-VI, sPLA2-IIE, and sPLA2-XIIA.

219 or, and was confirmed with BMEC derived from cPLA2 knockout mice.

220 Activation of cPLA2 leads to generation of intracellular arachidonic a

221 The C2 domain of cPLA2 linked to GFP translocates to the nuclear envelope

222 cPLA2 may play a key role in the pathogenesis of SCI, at

223 293 cells leads to significant inhibition of cPLA2-mediated arachidonate release.

224 rophages to UV radiation results in a rapid, cPLA2-mediated arachidonic acid mobilization, without in

225 vation conditions leads to inhibition of the cPLA2-mediated arachidonic acid mobilization.

226 Cytosolic phospholipase A2 (cPLA2) mediates agonist-induced arachidonic acid release

227 Basal cPLA2 messenger RNA (mRNA) expression was repressed 75%

228 Induced expression of cPLA2 mRNA by several proinflammatory cytokines was bloc

229 COX-2 of its substrate by the suppression of cPLA2 mRNA expression is an additional mechanism used by

230 e COX-2 of its substrate, AA, by suppressing cPLA2 mRNA expression.

231 y suppress the production of cytosolic PLA2 (cPLA2) mRNA.

232 itro, although to different extents, but not cPLA2 mutants that had Ser505 replaced by alanine.

233 l pretreatment with AACOCF3 (an inhibitor of cPLA2), nifedipine (a Ca(2+) channel blocker), or 3'-met

234 In Sf9 insect cells expressing cPLA2, okadaic acid, and the calcium-mobilizing agonists

235 s responsible for in vivo phosphorylation of cPLA2 on Ser-727.

236 jor effects on the expression or activity of cPLA2 or COX-2.

237 ntigen, it had no effect on translocation of cPLA2 or ERK1/2 activation, suggesting that it does not

238 in the level of cytosolic phospholipase A2 (cPLA2) or COX-1 were observed, and Group IIA sPLA2 was n

239 ands' cycle by knockdown of phospholipase 2 (cPLA2) or overexpression of lysophosphatidycholine acylt

240 cPLA2 overexpression and activation increased both IL-8

241 In this study, we show that cPLA2, p38 mitogen-activated protein kinase (MAPK), and

242 Remarkably, blocking cPLA2 pharmacologically at 30 minutes postinjury or gene

243 Finally, FMLP increases cPLA2 phosphorylation and arachidonic acid release.

244 LPS increases cPLA2 phosphorylation and arachidonic acid release.

245 H, caused complete inhibition of ADP-induced cPLA2 phosphorylation and TXA2 generation, without affec

246 ective inhibitors abolished 2MeSADP-mediated cPLA2 phosphorylation and TXA2 generation.

247 cal inhibition of p38 leads to inhibition of cPLA2 phosphorylation at both Ser-505 and Ser-727 sugges

248 In addition, JAK3 regulates cPLA2 phosphorylation independent of transcription.

249 embrane via a C2 domain, whereas the role of cPLA2 phosphorylation is less clearly defined.

250 dhesion to VCAM-1 corresponded temporally to cPLA2 phosphorylation, which accompanied enhanced cataly

251 Stimulation by TNF-alpha increases cPLA2 phosphorylation, which is inhibited by SB 203580,

252 r stimulation of human neutrophils increases cPLA2 phosphorylation.

253 e in intracellular calcium concentration nor cPLA2 phosphorylation; consequently, cPLA2 activity was

254 enase pathway showed that gene disruption of cPLA2 prevented the provision of arachidonic acid substr

255 It had little effect on levels of cPLA2 protein.

256 ncorporated similar levels of phosphate into cPLA2 relative to the ability of each kinase to stimulat

257 damage activates cytosolic phospholipase A2 (cPLA2), releasing arachidonic acid (AA), which is oxidiz

258 After [Ca2+]i decrease, cPLA2 remained associated with membrane in a Ca(2+)-inde

259 action of iPLA2 is immediate, the action of cPLA2 requires a lag time of approximately 12-15 min, pr

260 ACOCF3) and ShRNA mediated downregulation of cPLA2 resulted in reduced LDs, and increased autophagy.

261 ff assays showed a marked decline in de novo cPLA2 RNA synthesis, implicating a transcriptional mecha

262 ghts into the molecular mechanisms governing cPLA2's function in signal transduction.

263 s was associated with increased ERK mediated cPLA2(S505) phosphorylation.

264 l fluorophosphonate, a specific inhibitor of cPLA2, short interfering RNA against cPLA2, and several

265 port that activation of the host Raf-MEK-ERK-cPLA2 signaling cascade is required for the chlamydial u

266 be the major modulator of Src-PLD1-PKCgamma-cPLA2 signaling in HRMVECs, facilitating their angiogeni

267 sting an active manipulation of the host ERK-cPLA2 signaling pathway by chlamydiae.

268 ceptors 1 and 4, cytosolic phospholipase A2 (cPLA2), Src tyrosine kinases, p38 MAPK, phospholipase C,

269 ristic of the Ca2+-dependent cytosolic PLA2 (cPLA2) subtype.

270 There is an initial activation of cPLA2 that induces expression of Group V PLA2, which in

271 ible for the subsequent induction of type IV cPLA2 that mediates the release of arachidonic acid for

272 nts a novel structural class of inhibitor of cPLA2 that partitions into the phospholipid bilayer and

273 for the phosphorylation and translocation of cPLA2 to mitochondria.

274 isphosphate (PtdInsP2) in the association of cPLA2 to model membranes and hence in the regulation of

275 hought to be needed for translocation of the cPLA2 to the membrane via a C2 domain, whereas the role

276 FMLP/CB-stimulated translocation of cPLA2 to the nuclear envelope assessed by specific immun

277 ecessary and sufficient for translocation of cPLA2 to the nuclear envelope when calcium is increased;

278 slocation of green fluorescent protein (GFP)-cPLA2 to the nuclear envelope.

279 est and negligible effects on the binding of cPLA2 to zwitterionic and anionic membranes, respectivel

280 Translocation of cytosolic phospholipase A2 (cPLA2) to Golgi and ER in response to intracellular calc

281 chidonic acid, the major product of group IV cPLA2, to infected MPhi treated with cPLA2 inhibitors co

282 cPla2 translocation upon nuclear swelling was reconstitu

283 Ca(2+) was necessary but not sufficient for cPla2 translocation, and nuclear swelling was required i

284 The major enzymes in this pathway, cPLA2 type IVA, COX-2, and mPGES-1, were dramatically up

285 mediating the p25-induced LPC production and cPLA2 upregulation is critical in triggering the p25-med

286 When assaying the human recombinant cPLA2 using membranes isolated from [3H]arachidonate-lab

287 b and SAPK4 incorporated less phosphate, and cPLA2 was a poor substrate for SAPK3.

288 The chlamydia-induced phosphorylation of cPLA2 was also blocked by a dominant negative ERK2.

289 Furthermore, activation of both ERK1/2 and cPLA2 was dependent on chlamydial growth and restricted

290 Activated cPLA2 was localized mainly in neurons and oligodendrocyt

291 Expression of cPLA2 was low, and 5-LOX gene expression was not detecte

292 sPLA2 involved activation of cytosolic PLA2 (cPLA2) was next tested.

293 ype and phosphorylation site mutant forms of cPLA2, we show that phosphorylation of cPLA2 at both Ser

294 osphorylation of Ser505 and Ser727 activates cPLA2, we systematically analyzed the effects of S505A,

295 tern analyses revealed that these changes in cPLA2 were accompanied by a time-dependent gel shift of

296 f phosphorylation sites and the C2 domain of cPLA2 were investigated.

297 Ca(2+)-dependent cytosolic phospholipase A2 (cPLA2) were activated in chlamydia-infected cells.

298 through at least two pathways, TNF-alpha and cPLA2, which are both also critical for antimycobacteria

299 AA is generated by cPLA2, which may be stimulated through an AGE-activated

300 r) inhibited the phosphorylation of ERKs and cPLA2 without inhibition of several other tyrosine phosp